Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Kartini Hj Abdul Manaf was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jun 02
Full year 2026 earnings released: EPS: ₹0.15 (vs ₹7.57 loss in FY 2025) Full year 2026 results: EPS: ₹0.15 (up from ₹7.57 loss in FY 2025). Revenue: ₹19.8m (flat on FY 2025). Net income: ₹1.08m (up ₹48.8m from FY 2025). Profit margin: 5.5% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Tillkännagivande • May 26
Vanta Bioscience Limited to Report Second Half, 2026 Results on May 30, 2026 Vanta Bioscience Limited announced that they will report second half, 2026 results on May 30, 2026 Tillkännagivande • Nov 08
Vanta Bioscience Limited to Report First Half, 2026 Results on Nov 14, 2025 Vanta Bioscience Limited announced that they will report first half, 2026 results on Nov 14, 2025 Tillkännagivande • Sep 09
Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025 Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: 197, arun khetarpal rd, uma nagar colony, bowenpally, secunderabad-500009, secunderabad India Reported Earnings • Aug 02
Full year 2025 earnings released: ₹7.56 loss per share (vs ₹3.67 loss in FY 2024) Full year 2025 results: ₹7.56 loss per share (further deteriorated from ₹3.67 loss in FY 2024). Net loss: ₹47.7m (loss widened 106% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Jul 16
Vanta Bioscience Limited to Report Second Half, 2025 Results on Jul 19, 2025 Vanta Bioscience Limited announced that they will report second half, 2025 results on Jul 19, 2025 New Risk • Jun 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$536k). Market cap is less than US$10m (₹156.5m market cap, or US$1.83m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change). Tillkännagivande • May 21
Vanta Bioscience Limited to Report Q4, 2025 Results on May 30, 2025 Vanta Bioscience Limited announced that they will report Q4, 2025 results on May 30, 2025 New Risk • May 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$537k). Market cap is less than US$10m (₹153.6m market cap, or US$1.80m). New Risk • Apr 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$537k). Market cap is less than US$10m (₹152.8m market cap, or US$1.79m). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change). New Risk • Nov 16
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: ₹46m (US$543k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹43m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 62% per year over the past 5 years. Revenue is less than US$1m (₹46m revenue, or US$543k). Market cap is less than US$10m (₹259.9m market cap, or US$3.08m). Tillkännagivande • Nov 12
Vanta Bioscience Limited to Report First Half, 2025 Results on Nov 14, 2024 Vanta Bioscience Limited announced that they will report first half, 2025 results on Nov 14, 2024 Tillkännagivande • Sep 13
Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2024 Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time. Location: 197, arun khetarpal rd, uma nagar colony, bowenpally, secunderabad-500009, secunderabad India New Risk • Aug 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹7.2m free cash flow). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 70% per year over the past 5 years. Market cap is less than US$10m (₹351.9m market cap, or US$4.19m). Minor Risk Revenue is less than US$5m (₹98m revenue, or US$1.2m). Reported Earnings • Jul 25
Full year 2024 earnings released: ₹3.67 loss per share (vs ₹10.27 loss in FY 2023) Full year 2024 results: ₹3.67 loss per share (improved from ₹10.27 loss in FY 2023). Revenue: ₹98.3m (up 43% from FY 2023). Net loss: ₹23.2m (loss narrowed 64% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance. Tillkännagivande • Jul 11
Vanta Bioscience Limited to Report Second Half, 2024 Results on Jul 17, 2024 Vanta Bioscience Limited announced that they will report second half, 2024 results on Jul 17, 2024 New Risk • Jun 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹83m free cash flow). Earnings have declined by 76% per year over the past 5 years. Market cap is less than US$10m (₹360.0m market cap, or US$4.32m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Revenue is less than US$5m (₹103m revenue, or US$1.2m). Board Change • Feb 15
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jan 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 12
Full year 2023 earnings released: ₹10.27 loss per share (vs ₹0.14 profit in FY 2022) Full year 2023 results: ₹10.27 loss per share (down from ₹0.14 profit in FY 2022). Net loss: ₹64.8m (down ₹65.7m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 102 percentage points per year, which is a significant difference in performance. Tillkännagivande • Sep 07
Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2023 Vanta Bioscience Limited, Annual General Meeting, Sep 30, 2023, at 11:00 Indian Standard Time. Location: 197, Arun Khetarpal Rd, Uma Nagar Colony Sikh Village, Bowenpally, Secunderabad 500009 Telangana Andhra Pradesh India Board Change • Sep 04
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Aug 12
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: ₹70m (US$839k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Revenue is less than US$1m (₹70m revenue, or US$839k). Market cap is less than US$10m (₹371.1m market cap, or US$4.47m). Reported Earnings • Aug 11
Full year 2023 earnings released: ₹10.27 loss per share (vs ₹0.14 profit in FY 2022) Full year 2023 results: ₹10.27 loss per share (down from ₹0.14 profit in FY 2022). Net loss: ₹64.8m (down ₹65.7m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance. Tillkännagivande • Aug 05
Vanta Bioscience Limited to Report Second Half, 2023 Results on Aug 10, 2023 Vanta Bioscience Limited announced that they will report second half, 2023 results on Aug 10, 2023 Tillkännagivande • Jul 12
Vanta Bioscience Limited Announces Resignation of Vidisha Rathod as Company Secretary and Compliance Officer Vanta Bioscience Limited announced that Ms. Vidisha Rathod has resigned as Company Secretary and Compliance Officer of the Company with immediate effect July 10, 2023, due to her pre-occupations and personal reasons. The Company is in the process of appointing a new Company Secretary. In the interim, Mr. Dopesh Raja Mulakala, Managing Director is being appointed as the Compliance officer of the Company. Tillkännagivande • May 23
Vanta Bioscience Limited to Report Q4, 2023 Results on May 30, 2023 Vanta Bioscience Limited announced that they will report Q4, 2023 results on May 30, 2023 Tillkännagivande • Dec 08
Vanta Bioscience Limited, Annual General Meeting, Dec 31, 2022 Vanta Bioscience Limited, Annual General Meeting, Dec 31, 2022, at 10:00 Indian Standard Time. Location: 197, Arun Khetarpal Rd, Uma Nagar Colony, Sikh Village, Bowenpally, Secunderabad 500009 Telangana India Board Change • Dec 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Sep 16
Vanta Bioscience Limited Appoints Vidisha Rathod as Company Secretary and Compliance Officer Vanta Bioscience Limited announced that the company has appointed Ms. Vidisha Rathod as company secretary and compliance officer of the company, effective September 15, 2022. Ms. Vidisha Rathod is a qualified company secretary and an associate member of ICSI. She has over 5+ years of rich experience in Secretarial matters. She has previously worked as company secretary with Public Limited Companies like Chrysalis Finance Ltd., Mimanshu Industries Ltd. and Aatash Norcontrol Limited. She has exposure of handling various secretarial and legal matters. She is being appointed as CS and Compliance Officer, effective September 15, 2022 due to the resignation of existing CS. She is not associated with any of the Directors or KMPs of the company. Tillkännagivande • Sep 04
Vanta Bioscience Limited Announces Resignation of Zoheb S Sayani as Company Secretary / Compliance Officer Vanta Bioscience Limited announced the resignation of Mr. Zoheb S Sayani as the Company Secretary and Compliance officer of the Company w.e.f.15.09.2022 due to his pre-occupations. Board Change • Jul 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Jun 28
Insider recently bought ₹518k worth of stock On the 21st of June, Chandra Shekar Simhadri bought around 5k shares on-market at roughly ₹98.64 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Jun 03
Full year 2022 earnings released: EPS: ₹0.14 (vs ₹0.71 in FY 2021) Full year 2022 results: EPS: ₹0.14 (down from ₹0.71 in FY 2021). Revenue: ₹101.1m (flat on FY 2021). Net income: ₹882.0k (down 80% from FY 2021). Profit margin: 0.9% (down from 4.5% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Board Change • Jun 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Yogeswara Danda was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 04
Full year 2021 earnings released: EPS ₹0.71 (vs ₹1.59 in FY 2020) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹100.4m (down 29% from FY 2020). Net income: ₹4.50m (down 55% from FY 2020). Profit margin: 4.5% (down from 7.1% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 28% per year. Is New 90 Day High Low • Mar 03
New 90-day high: ₹150 The company is up 7.0% from its price of ₹140 on 03 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 3.0% over the same period. Tillkännagivande • Jan 06
Vanta Bioscience Limited Announces Resignation of Sadhanala Venkata Rao as Director Vanta Bioscience Limited announced that Mr. Sadhanala Venkata Rao has expressed his desire to resign from the services of the company and have not offered himself for re-appointment as Whole Time Director & CEO of the company post expiry of the term. Accordingly, he ceases to be the Whole Time Director of the company with effect from the close of working hours of January 4, 2021. Tillkännagivande • Jan 05
Vanta Bioscience Limited Announces Resignation of Sadhanala Venkata Rao as CEO Vanta Bioscience Limited announced that Mr. Sadhanala Venkata Rao has expressed his desire to resign from the services of the company and have not offered himself for re-appointment as Whole Time Director & CEO of the company post expiry of the term. Accordingly, he ceases to be the CEO of the company with effect from the close of working hours of January 04, 2021. Is New 90 Day High Low • Dec 28
New 90-day low: ₹124 The company is down 31% from its price of ₹180 on 28 September 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 17% over the same period. Is New 90 Day High Low • Dec 09
New 90-day low: ₹134 The company is down 18% from its price of ₹164 on 10 September 2020. The Indian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 19% over the same period. Tillkännagivande • Nov 14
Vanta Bioscience Limited Enters into Commercial Agreement with One of the Leading German Testing Agency Vanta Bioscience Limited announced that it has entered into a commercial agreement with one of the leading German Testing agency, wherein the Client has commissioned Vanta Bio to carry out Laboratory Testing Services in Biocompatibility and Analytics. The said agreement is valid for a period of 2 years. This is a major break through for the Company considering its decision to foray into Medical Devices vertical. This is not only an acknowledgement of the technical capabilities of Vanta Bio, but also validation of the world class services being provided by the Company. Over the period of association with the German Major, it will provide good exposure to international regulatory & testing requirements and help the Company to assimilate better testing capabilities, while gaining international recognition. Expected to generate a revenue of INR 100 million-INR 150 million approx. over the period of 2 years. Is New 90 Day High Low • Nov 04
New 90-day low: ₹148 The company is down 6.0% from its price of ₹157 on 06 August 2020. The Indian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period. Is New 90 Day High Low • Sep 23
New 90-day high: ₹170 The company is up 32% from its price of ₹129 on 25 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 37% over the same period. Tillkännagivande • Jun 20
Vanta Bioscience Limited to Report Fiscal Year 2020 Results on Jun 30, 2020 Vanta Bioscience Limited announced that they will report fiscal year 2020 results on Jun 30, 2020 
